Skip to main content

Table 1 Characteristics of included randomised controlled trials

From: Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

Randomised Controlled Trial (RCT) PubMed ID No. of participants Male (%) Follow-up (years)a Age (years)a HbA1c (%)a HbA1c (mmol/mol)a Diabetes duration (years)a Prevalent myocardial infarction (%) RCT calendar year (start–end) RCT typeb
UGDP 4926376 205 30.7 7.0 55.1 0 3.0 1961–1966 SD
UKPDS 33 9742976 1138 62.0 10.0 53.4 7.1 54.1 0 2.0 1977–1991 SD
DCGPc 23549519 620 53.1 5.8 65.4 10.2 88.0 0 7.7 1989–1991 SD
STENO-2 12556541 80 70.0 7.8 55.2 8.8 72.7 6.0 2.5 1993–1993 SD
JDCS 20054522 1016 53.0 7.8 58.6 7.9 62.8 10.9 0 1995–1996 SD
VADT 19092145 899 97.1 5.6 60.3 9.4 79.2 11.5 19.0 2000–2003 SD
PROactive 16214598 2633 66.0 2.9 61.6 7.9 62.8 8.0 46.1 2001–2002 PS
LOOK AHEAD 23796131 2575 40.3 9.6 58.9 7.3 56.3 5.0 6.1 2001–2003 SD
RECORD 19501900 2227 51.7 5.5 58.5 7.9 62.8 7.1 5.1 2001–2003 PS
ADVANCE 18539916 5569 57.7 5.0 66.0 7.5 58.5 8.0 12.0 2001–2003 SD
ACCORD 18539917 5123 61.6 3.5 62.2 8.3 67.2 10.0 18.1 2001–2005 SD
ADDITION 21705063 1379 57.3 5.3 60.2 7.0 53.0 0 6.1 2001–2006 SD
HEART2D 19246588 1115 63.3 2.7 61.0 8.3 67.2 9.1 100 2002–2005 SD
ORIGINd 22686416 6273 66.8 6.2 63.5 6.4 46.4 5.3 35.2 2003–2005 PS
TECOS 26052984 7339 70.5 3.0 65.5 7.2 55.2 11.6 42.5 2008–2012 PS
TOSCA 28917544 3028 58.5 4.8 62.3 7.7 60.6 8.4 6.4 2008–2014 PS
EXAMINE 23992602 2679 68.0 1.5 61.0 8.0 63.9 7.3 100 2009–2013 PS
CANVAS 28605608 4347 63.3 3.6 63.4 8.2 66.1 13.7 50.8 2009–2015 PS
SAVOR-TIMI 23992601 8212 66.6 2.0 65.0 8.0 63.9 10.3 37.6 2010–2011 PS
LEADER 27295427 4672 64.0 3.8 64.4 8.7 71.6 12.9 30.0 2010–2012 PS
ALECARDIO 24682069 3610 72.5 2.0 61.0 7.8 61.7 8.6 100 2010–2012 PS
ELIXA 26630143 3034 69.1 2.1 60.6 7.6 59.6 9.4 100 2010–2013 PS
EMPAREG 26378978 2333 72.0 2.9 63.2 8.1 65.0 9.5 46.4 2010–2013 PS
EXSCEL 28910237 7396 62.0 3.2 62.0 8.0 63.9 12.0 52.7 2010–2015 PS
SUSTAIN-6 27633186 1649 60.0 2.1 64.6 8.7 71.6 13.6 32.9 2013–2013 PS
DEVOTE 28605603 7637 62.6 2.0 50.0 8.4 68.3 16.4 34.1 2013–2014 PS
  1. Trials are listed by starting calendar year (older to newer) and number of participants (largest to smallest); their references are reported in the supplementary material. Data shown for control arm (except DEVOTE, TOSCA, HEART2D where arms were combined)
  2. aMean/median; bSD strategy-driven study, PS product-specific study; c563 total participants for total myocardial infarction outcome and 591 for total stroke; din ORIGIN, 11.15% of the population had impaired glucose tolerance or impaired fasting glucose at baseline
  3. – Not available